Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 10/2019

01-10-2019 | Care | Original Article

A population-based study of postfracture care in Manitoba, Canada 2000/2001–2014/2015

Authors: Y. Cui, L. M. Lix, S. Yang, S. N. Morin, W. D. Leslie

Published in: Osteoporosis International | Issue 10/2019

Login to get access

Abstract

Summary

We previously found that population-based postfracture notification, which informed primary care physicians of their patient’s recent fracture and suggested assessment for osteoporosis, led to an improvement in postfracture care in the context of a randomized controlled trial (ClinicalTrials.​gov identifier NCT00594789, fractures from late 2007 to mid-2010). Since June 2010, a province-wide postfracture notification program was implemented. This study was to (1) determine whether this program has resulted in sustained improvement in postfracture care and (2) test factors associated with receiving osteoporosis care.

Methods

A retrospective matched cohort study was performed using population-based health administrative data in Manitoba, Canada. We selected individuals aged 50+ years with an incident major osteoporosis fracture (MOF; N = 18,541) in fiscal years 2000/2001 to 2013/2014 and controls without a MOF (N = 92,705) matched (5:1) on age, sex, and residential area. The Cochran-Armitage test tested for a linear trend in osteoporosis care outcomes for cases and controls. Logistic regressions were used to test characteristics associated with the likelihood of receiving osteoporosis care.

Results

The percentage of individuals receiving DXA testing and/or osteoporosis medication increased in fracture cases (p < 0.001), but decreased in controls (p < 0.001). Odds ratios for osteoporosis care in years following the postfracture notification program were approximately double of those prior to the clinical trial. In addition to prior MOF (OR 9.03, 95% CI 8.60–9.48), factors associated with osteoporosis care included lower income (OR   0.72, 95% CI 0.67–0.78), glucocorticoid use (OR   4.37, 95% CI 3.72–5.14), diabetes diagnosis (OR =  0.74, 95% CI 0.68–0.80), and Charlson Comorbidity Index (indexes 1–2: OR 1.27, 95% CI 1.20–1.34; indexes 3–5: OR 1.26, 95% CI 1.13–1.40).

Conclusions

Adopting a population-based postfracture notification program led to sustained improvements in postfracture care.
Appendix
Available only for authorised users
Literature
1.
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3–44PubMed
2.
Papaioannou A, Kennedy CC, Ioannidis G et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703–714CrossRefPubMed
3.
Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181:265–271CrossRefPubMedPubMedCentral
4.
Tarride JE, Hopkins RB, Leslie WD, Morin S, Adachi JD, Papaioannou A et al (2012) The burden of illness of osteoporosis in Canada. J Bone Miner Res 27(8):1830–1838CrossRefPubMed
5.
Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC (2017) Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int 28(12):3289–3300CrossRefPubMed
6.
Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880CrossRefPubMed
7.
Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E (2016) Addressing the crisis in the treatment of osteoporosis. J Bone Miner Res 32(3):1929–1937
8.
Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY et al (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28(5):1507–1529CrossRefPubMedPubMedCentral
9.
Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone. 111:92–100CrossRefPubMed
10.
Sale JE, Beaton D, Posen J, Elliot-Gibson V, Bogoch E (2011) Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int 22(7):2067–2082CrossRefPubMed
11.
12.
13.
Roos LL, Roos NP, Cageorge SM, Nicol JP (1982) How good are the data? Reliability of one health care data bank. Med Care 20(3):266–276CrossRefPubMed
14.
Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32(11):1152–1157CrossRefPubMed
15.
Leslie WD, Metge C (2003) Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom 6(3):275–282CrossRefPubMed
16.
Leslie WD, Caetano PA, Macwilliam LR, Finlayson GS (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8(1):25–30CrossRefPubMed
17.
Lix LM, Azimaee M, Osman BA, Caetano P, Morin S, Metge C, Goltzman D, Kreiger N, Prior J, Leslie WD (2012) Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health 12:301CrossRefPubMedPubMedCentral
18.
O’Donnell S, Canadian Chronic Disease Surveillance System Osteoporosis Working G (2013) Use of administrative data for national surveillance of osteoporosis and related fractures in Canada: results from a feasibility study. Arch Osteoporos 8:143CrossRefPubMedPubMedCentral
19.
Epp R, Alhrbi M, Ward L, Leslie WD (2018) Radiological validation of fracture definitions from administrative data. J Bone Miner Res 33(Supp 1):S275
20.
Brownell M, Mayer T, Martens PJ, Kozyrskyj A, Fergusson P, Bodnarchuk J et al (2002) Using a population-based health information system to study child health. Can J Public Health 93(Suppl 2):S9–S14CrossRefPubMedPubMedCentral
21.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139CrossRefPubMed
22.
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682CrossRefPubMed
23.
Lix LM, Yogendran MS, Shaw SY, Burchill C, Metge C, Bond R (2008) Population-based data sources for chronic disease surveillance. Chronic Dis Can 29(1):31–38PubMed
24.
SAS Institute Inc (2016) SAS® 9.4 system options: reference, Fifth Edition. SAS Institute Inc., Cary
25.
26.
Leslie WD, Brennan SL, Prior HJ, Lix LM, Metge C, Elias B (2012) The post-fracture care gap among Canadian First Nations peoples: a retrospective cohort study. Osteoporos Int 23(3):929–936CrossRefPubMed
27.
Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int 28(8):2485–2494CrossRefPubMedPubMedCentral
28.
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, for the Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873CrossRefPubMedPubMedCentral
29.
30.
31.
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentral
32.
Greenspan SL, Wyman A, Hooven FH, Adami S, Gehlbach S, Anderson FA Jr et al (2012) Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc 60(3):455–461CrossRefPubMedPubMedCentral
33.
Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128(5):519–526CrossRefPubMedPubMedCentral
34.
Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97(19):1555–1562CrossRefPubMed
35.
Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937CrossRefPubMed
36.
Beaton DE, Mamdani M, Zheng H, Jaglal S, Cadarette SM, Bogoch ER (2017) Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program: an interrupted time series analysis. Medicine. 96(48):e9012CrossRefPubMedPubMedCentral
37.
Majumdar SR, Lier DA, Leslie WD (2013) Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial. J Clin Endocrinol Metab 98(5):1991–2000CrossRefPubMed
38.
39.
Metadata
Title
A population-based study of postfracture care in Manitoba, Canada 2000/2001–2014/2015
Authors
Y. Cui
L. M. Lix
S. Yang
S. N. Morin
W. D. Leslie
Publication date
01-10-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 10/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-05074-8

Other articles of this Issue 10/2019

Osteoporosis International 10/2019 Go to the issue

Original Article

Association between trabecular bone score and type 2 diabetes: a quantitative update of evidence

Review

Heart failure and fracture risk: a meta-analysis

Original Article

Bisphosphonates and mortality: confounding in observational studies?

Original Article

The renin-angiotensin aldosterone system and osteoporosis: findings from the Women’s Health Initiative

Original Article

Assessing risk factors of non-fatal outcomes amid a competing risk of mortality: the example of hip fracture

Original Article

Association between serum uric acid and bone health in adolescents